You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥板塊續受捧 翰森、泰格、君實、百濟神州、德琪及藥明巨諾漲8%-13%
期結日,恆指今早低開173點或1%報17,225獲承接,掉頭曾倒升高見17,401,現報17,329,回吐69點或0.4%,總成交額450億元。此外,國指報5,919,回吐1%。 里昂上周發表報告調研200名投資者大多數對醫療板塊呈正面,以及大和上周亦維持看好醫藥板塊。醫藥股今天普遍延續上周五強勢,尤其是百濟神州(06160.HK)今早低開報103.4元獲承接,掉頭升破50天線(114.4元),最高見116.8元,現報116.5元,續漲11%。藍籌翰森(03692.HK)今早股價低見報13.92元獲承接,掉頭高見15.18元,創逾半年高,現報15.16元,續升7.7%。 君實生物(01877.HK)公布,合作合作夥伴Coherus特瑞普利單抗(治療鼻咽癌)FDA批准上市。該股今早裂口高開14.5%報22.7元欠承接,曾回順至21.1元,現報21.4元,續升8%,100天線(21.56元)得而復失。第三季多賺19%的泰格醫藥(03347.HK)挑戰百天線(44.6元),最高見44.95元,現報44.4元,續升7.8%。 藍籌中生製藥(01177.HK)高見3.1元創近兩個月高,現報3.06元,續升4.8%。同為藍籌藥明生物(02269.HK)擬分拆旗下藥明合聯已通過上市聆訊。該股今天重越250天線(48.75元)高見50.9元,現報50.7元,續升6.2%;藥明康德(02359.HK)高低見103.6元/97.45元,現報101.3元,續升3.2%。藥明巨諾(02126.HK)續升13%報2.12元,股價重越50天線(2.11元)。 德琪醫藥(06996.HK)續升12%報1.41元,股價重越100天線(1.39元)。信達生物(01801.HK)高見48.55元,創近十個月高,現報47.65元,續升5.9%。康希諾(06185.HK)續升5.6%報25.35元。 開拓(09939.HK)、三葉草生物-B(02197.HK)、騰盛博藥-B(02137.HK)、金斯瑞生物(01548.HK)、四環醫藥(00460.HK)續升2%-5%。 沛嘉醫療(09996.HK)續升14%,股價高見7.62元,現報7.47元,續升13%;環亞國際醫療(01143.HK)高見1.86元,現報1.79元,回升8.5%。 然而,首三季多賺4%報60.96億人民幣的藍籌國藥(01099.HK)逆市低見19.06元,創逾九個月低,現報19.28元,逆吐3%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account